CULLINAN THERAPEUTICS, INC. Shareholders' Equity
CULLINAN THERAPEUTICS, INC. (CGEM) had Shareholders' Equity of $408.73 million as of 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-03-10
- 2025-12-31: Stockholders' Equity Attributable to Parent $408.73M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $451.37M.
- 2025-06-30: Stockholders' Equity Attributable to Parent $492.15M.
- 2025-03-31: Stockholders' Equity Attributable to Parent $551.84M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2025-12-31 | $408.73M 10-K · filed 2026-03-10 |
| 2025-09-30 | $451.37M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $492.15M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $551.84M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $590.33M 10-K · filed 2026-03-10 |
| 2024-09-30 | $627.86M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $656.22M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $425.67M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $453.70M 10-K · filed 2025-02-27 |
| 2023-09-30 | $468.82M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $499.57M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $485.65M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $535.03M 10-K · filed 2024-03-14 |
| 2022-09-30 | $586.13M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $604.54M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $418.70M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $424.97M 10-K · filed 2023-03-09 |
| 2021-09-30 | $443.39M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $455.55M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $466.90M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $199.01M 10-K · filed 2022-03-17 |
| 2020-09-30 | $87.65M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $97.65M 10-Q · filed 2021-08-10 |
| 2019-12-31 | $97.00M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |